PAGE 01/04

## RECEIVED

FEB 2 7 2004

## **CENTRAL FAX CENTER**

## FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP 666 FIFTH AVENUE, 315T FLOOR NEW YORK, NEW YORK 10103-3198 WWW.FULBRIGHT.COM

#### FACSIMILE TRANSMISSION

DATE:

February 27, 2004

MATTER NUMBER:

10109389

RECIPIENT(S):	FAX No.:	PHONE NO.:				
Examiner Susan Ungar	1703 305-7230	1703 305-2181				
Group Art Unit 1642	17038729306					
COmmissioner for Patents	13 10 30					

D.	A3.54	
HК	om:	

Norman Hanson

USER ID:

NH01030

FLOOR:

24

PHONE:

(212) 318-3168

FAX:

(212) 318-3400

RE:

U.S. Serial No. 09/975,856

LUD 5480.2 DIV

NUMBER OF PAGES WITH COVER PAGE:

Message:		 
ļ		

#### **CAUTION - CONFIDENTIAL**

THE INFORMATION CONTAINED IN THIS FACSIMILE IS CONFIDENTIAL AND MAY ALSO CONTAIN PRIVILEGED ATTORNEY-CLIENT INFORMATION OR WORK PRODUCT. THE INFORMATION IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHOM IT IS ADDRESSED. IF YOU ARE NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT ANY USE. DISSEMINATION, DISTRIBUTION OR COPYING OF THIS COMMUNICATION IS STRICTLY PROBERTED. IF YOU HAVE RECEIVED THE FACSIMILE IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND RETURN THE ORIGINAL MESSAGE TO US AT THE ADDRESS ABOVE VIA THE U.S. POSTAL SERVICE. THANK YOU.

#### LUD 5480.2 DIV (10109389)

### CERTIFICATE OF FACSIMILE TRANSMITTAL

I hereby certify that this correspondence is being transmitted via telecopy pursuant to 37 C.F.R. § 1.8 to <u>Group 1642</u>, <u>Examiner Susan Ungar</u> of the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 at fax number (703) 305-7230 on February 27, 2004.

Fani Malikouzakis (Name of Transmitter)

(Signature)

RECEIVED
CENTRAL FAX CENTER

FEB 2 7 2004

### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s):

GURE et al.

Serial No

09/975,856

Filed:

October 11, 2001

For

ANTIBODIES SPECIFIC FOR SSX PROTEINS

Art Unit

1642

Examiner

Susan UNGAR

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

# RESPONSE TO RESTRICTION REQUIREMENT AND AMENDMENT

SIR:

This is submitted in response to the Office Action of February 17, 2004.

In response to that action, applicants elect Group III; however, it is believed that the Examiner mischaracterizes the scope of the claims.

Claim 24 depends from claim 20, which is NOT limited to SEQ ID NO: 1. Rather, there are two options, recognized by the Examiner as per, e.g., Group I. As such, applicants are rewriting claim 24, which is a dependent claim, to reflect this.

Please amend this application as follows:

#### LUD 5480.2 DIV (10109389)

#### IN THE CLAIMS

Claims 1-24. (Canceled)

- (New) A method for determining expression of an SSX4 gene, comprising Claim 25. contacting a sample with an isolated antibody which specifically binds to a protein (i) encoded by an isolated nucleic acid molecule having the nucleotide sequence of SEQ ID NO: 1, or (ii) encoded by an isolated nucleic acid having nucleotides 1-330 of SEQ ID NO: 1, concatenated to nucleotides 467-576 of SEQ ID NO: 1, and determining binding of said antibody to a target as a determination of expression of SSX4.
- Claim 26. (New) The method of claim 25, wherein binding of said antibody to said target as a determination of expression of SSX4 is indicative of cancer cells being present in said sample.
- Claim 27. (New) The method of claim 26, wherein said cancer is melanoma.

## LUD 5480.2 DIV (10109389)

## REMARKS

Claim 25 presents elected claim 24, in independent form. Claims 26 and 27 are supported by pages 15 and 16 of the specification.

Examination of this application is requested.

Respectfully submitted,

FULBRIGHT & JAWORSKI, L.L.P.

Norman D. Hanson, Esq. Registration No. 30,946

666 Fifth Avenue

New York, New York 10103-3198

Telephone: 212-318-3168 Telecopier: 212-318-3400